Selective estrogen receptor modulators (SERMs) are the most common drug group used in ER-positive breast cancer treatment with tamoxifen as the first line agent used to block mitogenic effects of estrogen at all stages of breast cancer, particularly in pre- and post-menopausal patients (Abdulkareem & Zurmi, 2012). This evidence concerns the gene ESR1 and breast cancer.